---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005418"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:19:36.096617+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EyePoint provides 2026 clinical milestones; ~$300M cash; wet AMD data mid-2026

## Summary
- Phase 3 LUGANO (432 pts) wet AMD top-line data expected mid-2026; LUCIA (475 pts) data to follow.
- Phase 3 DME program (COMO/CAPRI) first patient dosing expected Q1 2026; ~240 pts each.
- Preliminary cash & investments ~$300M at Dec 31, 2025; runway into Q4 2027.
- DSMC second review recommended continuation of Phase 3 program with no protocol changes.
- Presenting at J.P. Morgan Healthcare Conference on Jan 13, 2026 at 7:30 a.m. PT.

## SEC filing metadata
- accession: 0001193125-26-005418
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526005418/0001193125-26-005418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526005418/eypt-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005418
- JSON: https://secwatch.observer/filing/0001193125-26-005418.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.